The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in PubMed. This abstract is what is used to create the fingerprint of the publication. If any grants are referenced by the publication, they will be listed here as well.
Nevirapine-Associated Hepatotoxicity and Rash among HIV-Infected Pregnant Women in Kenya.
Philip J Peters; Nicholas Polle; Clement Zeh; Rose Masaba; Craig B Borkowf; Boaz Oyaro; Paul Omolo; Paul Ogindo; Richard Ndivo; Frank Angira; et al. (Profiled Author: Mary Fowler)
1Centers for Disease Control and Prevention, Atlanta, GA, USA.
Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 2012;11(2):142-9.
UNLABELLED: Background: Few studies have evaluated the risk of nevirapine (NVP)-associated hepatotoxicity among HIV-infected pregnant women with a CD4 count ≥250 cells/mm(3). METHODS: We enrolled HIV-infected pregnant Kenyan women who initiated triple antiretroviral therapy (ART) at 34 weeks gestation. We compared the rates of severe hepatotoxicity (grades 3-4 hepatotoxicity) and rash-associated hepatotoxicity (rash with ≥grade 2 hepatotoxicity) with NVP and nelfinavir (NFV), respectively. RESULTS: We initiated triple ART in 522 pregnant women; severe hepatotoxicity and rash-associated hepatotoxicity occurred in 14 (3%) and 9 (2%) women, respectively. Women who initiated NVP had higher rates of severe hepatotoxicity (5% vs 1%; P = .03) and rash-associated hepatotoxicity (4% vs 0%; P = .003) when compared with NFV. Among women who initiated NVP (n = 254), a baseline CD4 count ≥250 cells/mm(3) was not associated with severe hepatotoxicity (5% vs 3%; P = .52) or rash-associated hepatotoxicity (4% vs 3%; P = .69). CONCLUSION: Nevirapine use but not CD4 count ≥250 cells/mm(3) was associated with hepatotoxicity.
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts and related grants with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
Michael D Sweat; Kevin R O'Reilly; George P Schmid; Julie Denison; Isabelle de ZoysaAIDS (London, England) 2004;18(12):1661-71.
Jim Aizire; Mary Glenn Fowler; Jing Wang; Avinash K Shetty; Lynda Stranix-Chibanda; Moreen Kamateeka; Elizabeth R Brown; Steve G Bolton; Philippa M Musoke; Hoosen CoovadiaAIDS (London, England) 2012;26(3):325-33.
A Wiznia; K Stanley; P Krogstad; G Johnson; S Lee; J McNamara; J Moye; J B Jackson; H Mendez; R Aguayo; et al.
Combination nucleoside analog reverse transcriptase inhibitor(s) plus nevirapine, nelfinavir, or ritonavir in stable antiretroviral therapy-experienced HIV-infected children: week 24 results of a randomized controlled trial--PACTG 377. Pediatric AIDS Clinical Trials Group 377 Study Team.AIDS research and human retroviruses 2000;16(12):1113-21.
Appears in this Publication
Author of this Publication